Methotrexate Pfizer (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the regeneration of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition reduces the replication of rapidly dividing cells such as activated immune cells and cancer cells, providing immunosuppressive and antineoplastic effects.

The dose is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. Methotrexate dosing regimens vary widely, so the prescriber sets the exact amount and schedule for each patient.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended during breastfeeding, as it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate belongs to the antimetabolite class and differs from biologic agents such as TNF inhibitors by directly inhibiting folate metabolism. Compared with other chemotherapy drugs, it has a well‑characterised safety profile and is often used at lower doses for autoimmune diseases, whereas higher doses are employed in oncology.

Methotrexate Pfizer should be stored at 2‑8 °C, protected from light, and kept in its original packaging to avoid moisture. Do not freeze the product, and handle it with gloves to prevent skin exposure. Once removed from refrigeration, use within the time frame specified by the manufacturer.

Methotrexate is administered by injection via intra‑arterial, intramuscular, or intrathecal routes, depending on the clinical indication. The healthcare professional prepares the dose under aseptic conditions and delivers it according to the prescribed schedule, which may be weekly, bi‑weekly, or as a single high‑dose infusion for certain cancers.

The most serious adverse events include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, and renal failure due to drug precipitation. Patients should be monitored regularly for liver enzymes, blood counts, lung symptoms and renal function, and any signs of infection should be reported promptly.

Methotrexate is contraindicated in pregnant or nursing women, patients with severe hepatic impairment, uncontrolled renal disease, active infections, and those with known hypersensitivity to methotrexate or its excipients. Caution is also advised for individuals with a history of pulmonary disease or alcohol abuse.